Asia
AstraZeneca announced a series of wins in Japan with regulatory approvals for Tagrisso, Ultomiris and Lynparza, to treat non-small cell lung cancer, myasthenia gravis and breast cancer, respectively.
Russian researchers announced a new Sputnik V vaccine against the Delta and Omicron variants of COVID-19, AB Science files for conditional marketing approval of its ALS drug in the EU and much more.
Ryvu and Opthea have new funding to work with, Tessa Therapeutics and Enlivex kick off new trials and Revive Therapeutics amends the Phase III protocol for its COVID-19 hopeful.
The Bill & Melinda Gates Foundation inked a memorandum of understanding with South Korea’s foreign and health ministries to expand their partnerships revolving around public health.
Panacell Biotech plans to initiate a program to investigate the use of natural killer (NK) immune cells, exosomes and brown adipose-derived stem cells to treat Long COVID.
The big Connect in Pharma conference is coming up with digitization and supply chain on the agenda and CanSino Biologics, HUTCHMED and more have positive research news.
The agreement will grant Innovent exclusive development and marketing rights to tusamitamab in China, while Sanofi will be entitled to up to $81 million in milestones and royalties.
Here’s a look at global biopharma company news stories including Rona Therapeutics, Genuine Bio and NEOsphere Bio.
In 2000, China did not have one company on the Forbes Global 2000 list. In 2021, it had 14. This is good for second place on this list, behind the United States which had 31.
Maxvax and Luzhu are raising funds to move their respective research and development programs for recombinant herpes zoster vaccine candidates and new adjuvant products.
PRESS RELEASES